UROLOGY CASE STUDY
History of Present Illness (HPI) Presents with chief complaint of: • Increased urinary frequency • Painful urination
Medical History • Hyperlipidemia • Erectile Dysfunction • Negative biopsy 3 years ago
Family History • Father diagnosed with prostate cancer
at 64
Clinical Assessment • Key factors to consider? • Severity/duration of
symptoms? • Differential diagnosis?
Patient: Doug* Age: 62 68
Most Recent PSA Score: 4.6
Test Results PSA tested annually since age 52. Scores range from 2.3 – 4.9
Clinical Decision • Change in follow-up/
monitoring? • Follow-up labs? • Imaging? • Biopsy?
*Hypothetical patient profile
What is APIFINY®? APIFINY is the only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer.
When should I order APIFINY? APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy.
Why should I order APIFINY? APIFINY measures certain specific biological markers that may provide you with additional insight to aid in a clinical decision for determining your patient’s risk of prostate cancer.
UROLOGY CASE STUDY
Patient: George* Age: 50
History of Present Illness (HPI) Presents upon referral from primary care: • Nocturia (slightly worse over past year) • Normal digital rectal exam (DRE) • Normal urinalysis (UA)
Medical History • Hypertension (HTN) • Erectile Dysfunction
Family History • Father died of a heart attack at age 60
Clinical Assessment • Key factors to consider? • Severity/duration of
symptoms? • Differential diagnosis?
Test Results PSA tested annually since age 42. Scores range from 2.6 – 3.7
54
Most Recent PSA Score: 4.5
Clinical Decision • Change in follow-up/
monitoring? • Follow-up labs? • Imaging? • Biopsy?
*Hypothetical patient profile
What is APIFINY®? APIFINY is the only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer.
When should I order APIFINY? APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy.
Why should I order APIFINY? APIFINY measures certain specific biological markers that may provide you with additional insight to aid in a clinical decision for determining your patient’s risk of prostate cancer.
UROLOGY CASE STUDY
Patient: Robert* Age: 45
History of Present Illness (HPI) Presents for routine annual exam: • Mildly enlarged prostate gland • Negative review of symptoms (ROS)
Medical History • Hypertension (HTN) • Vasectomy 5 years ago • Negative biopsy 2 years ago
Family History • Grandfather diagnosed with prostate
cancer at 54
Clinical Assessment • Key factors to consider? • Severity/duration of
symptoms? • Differential diagnosis?
Test Results PSA tested annually since age 40. Scores range from 2.8 – 4.7
Most Recent PSA Score: 4.6
22
Clinical Decision • Change in follow-up/
monitoring? • Follow-up labs? • Imaging? • Biopsy?
*Hypothetical patient profile
What is APIFINY®? APIFINY is the only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer.
When should I order APIFINY? APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy.
Why should I order APIFINY? APIFINY measures certain specific biological markers that may provide you with additional insight to aid in a clinical decision for determining your patient’s risk of prostate cancer.
UROLOGY CASE STUDY
Patient: Peter* Age: 55
History of Present Illness (HPI) Presents upon referral from primary care: • Denies any symptoms (negative ROS) • Normal urinalysis (UA) • Mildly enlarged prostate gland
Medical History • Hypertension (HTN) • Negative prostate biopsy 5 years prior
Family History • No known history of prostate cancer
Clinical Assessment • Key factors to consider? • Severity/duration of
symptoms? • Differential diagnosis?
Test Results PSA tested annually since age 42. Scores range from 2.3 – 4.5
92
Most Recent PSA Score: 4.2
Clinical Decision • Change in follow-up/
monitoring? • Follow-up labs? • Imaging? • Biopsy?
*Hypothetical patient profile
What is APIFINY®? APIFINY is the only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer.
When should I order APIFINY? APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy.
Why should I order APIFINY? APIFINY measures certain specific biological markers that may provide you with additional insight to aid in a clinical decision for determining your patient’s risk of prostate cancer.
www.armune.com 6
APIFINY® – Results Interpretation
Lower risk of prostate cancer. Score not consistent with prostate cancer. “In the most recent peer-reviewed published study on Apifiny1, approximately 9 out of 10 men like you, with a score of less than 59, were cancer free.” Potential clinical decision2: Combine with other clinical information to determine next steps. Continue routine clinical monitoring.
Higher risk of prostate cancer. Score consistent with prostate cancer. “In the most recent peer-reviewed published study on Apifiny1, approximately 1 out of 3 men like you, with a score of 59 or above, had prostate cancer. You may be at higher risk.” Potential clinical decision2: Combine with other clinical information to determine next steps. Develop an individualized patient management plan and consider a prostate biopsy
APIFINY® Prostate Cancer
Risk Assessment
Lower Risk
Higher Risk
0 59 100
1. Translational Oncology, April 2015, Volume 8 Number 2: 106-111 2. Physician utilization market research (2015)
Top Related